Skip to main content

Alan vs Nabla

Side-by-side on valuation, funding, investors, founders & more

Comparison updated: April 2026

Alan is valued at $5.8B — more than 3x Nabla's $180M.

Head-to-Head Verdict

Alan leads on 5 of 5 metrics

Alan

5 wins

+Valuation
+Funding
+Awaira Score
+Team Size
+Experience

Nabla

0 wins

-Valuation
-Funding
-Awaira Score
-Team Size
-Experience

Key Numbers

Valuation
$5.8B
$180M
Total Funding
$750M
$131M
Awaira Score
83/100
73/100
Employees
500-1000
80
Founded
2016
2018
Stage
Series D
Series C
AlanNabla
Winner
Alan logo
Alan

🇫🇷 France · Jean-Charles Samuelian

Series DAI HealthcareEst. 2016

Valuation

$5.8B

Total Funding

$750M

Awaira Score83/100

500-1000 employees

Full Alan Profile →
Nabla logo
Nabla

🇫🇷 France · Alexandre Lebrun

Series CAI HealthcareEst. 2018

Valuation

$180M

Total Funding

$131M

Awaira Score73/100

80 employees

Full Nabla Profile →
Market Context

Alan and Nabla are both AI Healthcare companies based in France, making this a direct domestic rivalry. The stage gap — Alan at Series D vs Nabla at Series C — shapes how each company allocates capital and talent.

🔬

Analyst Summary

Built from real data · Updated April 2026

Companies

The AI Healthcare sector features both Alan and Nabla as key players. Alan is an AI-powered health insurance platform that combines employer group health insurance products with a digital health companion application, using AI to personalise member health recommendations, streamline claims processing, and provide on-demand access to telehealth and mental health resources. Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows.

Funding & Valuation

At $5.8B, Alan's valuation dwarfs Nabla's $180M by a factor of 32.4. With $750M raised, Alan has attracted substantially more capital than Nabla ($131M).

Growth Stage

Established in 2016, Alan has a modest 2-year head start over Nabla (2018). Stage-wise, Alan is classified as Series D and Nabla as Series C, reflecting divergent fundraising histories. On headcount, Alan reports 500-1000 employees and Nabla reports 80.

Geography & Outlook

Both companies are headquartered in 🇫🇷 France, competing for the same regional talent pool and customer base. Awaira rates Alan at 83 and Nabla at 73, a gap that reflects differences in capital efficiency and market traction. Alan, led by Jean-Charles Samuelian, and Nabla, led by Alexandre Lebrun, each bring distinct leadership visions to the AI sector.

Funding Velocity

Alan

Total Rounds1
Avg. Round Size$183M

Nabla

Total Rounds1
Avg. Round SizeN/A

Funding History

Alan has completed 1 funding round, while Nabla has gone through 1. Alan's most recent round was a Series E of $183M, compared to Nabla's Seed. Alan is at Series D while Nabla is at Series C — different points in their growth trajectory.

Team & Scale

Alan is significantly larger with about 500-1000 employees, compared to Nabla's 80. That's a 6x difference in headcount. They're close in age — Alan started in 2016 and Nabla in 2018. Both are based in France.

Metrics Comparison

MetricAlanNabla
💰Valuation
$5.8BWINS
$180M
📈Total Funding
$750MWINS
$131M
📅Founded
2016
2018WINS
🚀Stage
Series D
Series C
👥Employees
500-1000
80
🌍Country
France
France
🏷️Category
AI Healthcare
AI Healthcare
Awaira Score
83WINS
73

Key Differences

💰

Valuation gap: Alan is valued 32.4x higher ($5.8B vs $180M)

📈

Funding gap: Alan has raised $619M more ($750M vs $131M)

📅

Market experience: Alan has 2 years more (founded 2016 vs 2018)

🚀

Growth stage: Alan is at Series D vs Nabla at Series C

👥

Team size: Alan has 500-1000 employees vs Nabla's 80

⚔️

Direct competitors: Both operate in the AI Healthcare market segment

Awaira Score: Alan scores 83/100 vs Nabla's 73/100

Which Should You Choose?

Use these signals to make the right call

Alan logo

Choose Alan if…

Top Pick
  • Higher Awaira Score — 83/100 vs 73/100
  • More established by valuation ($5.8B)
  • Stronger investor backing — raised $750M
  • More market experience — founded in 2016
  • Alan is an AI-powered health insurance platform that combines employer group health insurance products with a digital health companion application, using AI to personalise member health recommendations, streamline claims processing, and provide on-demand access to telehealth and mental health resources
Nabla logo

Choose Nabla if…

  • Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows

Funding History

Alan raised $750M across 1 round. Nabla raised $131M across 1 round.

Alan

Series E

Oct 2022

Lead: Coatue Management

$183M

Nabla

Seed

Jan 2018

Investor Comparison

No shared investors detected between these two companies.

Unique to Alan

Coatue ManagementDragoneerTemasek

Users Also Compare

FAQ — Alan vs Nabla

Is Alan bigger than Nabla?
By valuation, Alan is the larger company at $5.8B versus $180M — a 32.4x difference. Size can also be measured by team: Alan employs 500-1000 people while Nabla has 80 employees.
Which company raised more funding — Alan or Nabla?
Alan has raised more in total funding at $750M, compared to Nabla's $131M — a gap of $619M. Combined, the two companies have completed 2 known funding rounds.
Which company has a higher Awaira Score?
Alan leads with an Awaira Score of 83/100, while Nabla sits at 73/100. That 10-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.
Who founded Alan vs Nabla?
Alan was founded by Jean-Charles Samuelian in 2016. Nabla was founded by Alexandre Lebrun in 2018. Visit each company's profile on Awaira for a full founder biography.
What does Alan do vs Nabla?
Alan: Alan is an AI-powered health insurance platform that combines employer group health insurance products with a digital health companion application, using AI to personalise member health recommendations, streamline claims processing, and provide on-demand access to telehealth and mental health resources. The Paris company holds full insurance carrier status in France, Belgium, and Spain, operating as a licensed insurer rather than a distribution intermediary.\n\nThe company raised approximately $220 million including a Series D round from investors including Temasek, Coatue, and Index Ventures, reaching a valuation of approximately $1.4 billion. Alan reports over half a million members across its markets, covering employees at several thousand companies including Stripe, Spendesk, and Vinted, with strong growth in SME employer sales driven by its digital-first enrolment and claims experience. The Alan app provides members with health navigation, symptom checking, and AI-generated health content in addition to insurance card and claims management functionality.\n\nAlan competes in the European digital health insurance market against traditional mutuals including Malakoff Humanis and AG2R La Mondiale, as well as digital health insurers including Henner and Oscar Health in the US context. Its vertical integration as a licensed insurer combined with a technology platform differentiates it from insurtechs that distribute existing insurer products through digital channels, giving Alan full control over the member experience and claims economics. The company is considered one of the most significant French technology companies building in regulated financial services. Nabla: Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows. The company has raised $30M in total funding and operates at Series B stage with a valuation of $200M. Nabla's core offering focuses on AI-powered clinical documentation tools designed to reduce administrative burden on healthcare providers. The platform applies natural language processing and machine learning to automate medical note-taking, allowing physicians to spend more time with patients rather than on paperwork. The company targets hospitals, clinics, and healthcare systems across Europe, with particular strength in the French market. Nabla's technology integrates with existing electronic health record systems and clinical workflows. The company competes in the growing digital health and healthcare AI sector alongside players focused on clinical automation and documentation efficiency. Nabla's approach emphasizes practical integration into existing healthcare infrastructure rather than building standalone applications. The company has demonstrated traction in European healthcare markets where administrative burden on clinicians remains significant. Its Series B funding stage indicates successful product-market fit validation and positions Nabla for expanded market reach and product development in the healthcare AI space. Nabla addresses the specific pain point of clinical documentation burden through AI automation, allowing European healthcare providers to improve operational efficiency.
Which company was founded first?
Alan got there first, launching in 2016 — that's 2 years of extra runway. Nabla didn't arrive until 2018. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.
Which company has more employees?
Alan has about 500-1000 employees; Nabla has about 80. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.
Are Alan and Nabla competitors?
Yes — they're direct rivals. Both Alan and Nabla compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.

Bottom Line

Alan edges ahead with an Awaira Score of 83, but Nabla (73) isn't far behind. The gap is narrow enough that it could shift with the next funding round.

Who Should You Watch?

Alan has a slight edge on paper, but Nabla isn't far behind. The AI space moves fast — today's underdog can be tomorrow's category leader. Follow both profiles on Awaira to track funding rounds, team changes, and score updates.

Deep Dive